Weekly Roundup: August 2-6

ICYMI, some of this week’s featured content includes a new podcast episode, video interviews about FDA delays and sunscreen recalls, articles on topline study results for alopecia areata and utilizing the psoriasis toolbox, plus more.

POLL: Which medium do you prefer to consume your dermatology news?

Meet the Aesthetic Expert with Dr Will Kirby: Edrice Simmons

In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Edrice Simmons, senior vice president for US brands for Allergan Aesthetics, an AbbVie company, about entering the aesthetics industry, innovation, and implementing approachable and representative marketing campaigns.

Doctors Aim for Better Understanding of Pediatric Melanoma Through Registry

In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).

Behind the Scenes at the ABM Perspectives Symposium

Take a look behind the scenes at the Aesthetics Biomedical's "Perspectives: The Evolution of Aesthetics" symposium held July 24th in Orlando, Florida.

MediWound Announced Positive Phase 3 Trial Results

MediWound Ltd, announced the results for its CIDS trial studying NexoBrid as a treatment for children with severe thermal burns.

FDA Grants Fast Track Designation to Nemvaleukin Alfa for Mucosal Melanoma

Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.

The Mainstream Patient: August 4, 2021

This week’s edition of The Mainstream Patient features stories about purchasing non-toxic sunscreen, biologics for psoriasis, biotin for hair growth, "bacne", plus more.

Twyneo Approval Shakes up Acne Treatment World

Joshua Zeichner, MD, associate professor of dermatology and director of cosmetic & clinical research in dermatology, Mount Sinai Hospital, New York, discusses the impact of the recent FDA approval of Twyneo (Sol-Gel) for the treatment of acne.

Valisure CEO Shares Thoughts on Johnson & Johnson Sunscreen Recall

In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).

Utilizing the Psoriasis Toolbox

In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.

Ritlecitinib Delivers Topline Results in Alopecia Areata Study

Ritlecitinib, an investigational covalent kinase inhibitor, achieved its primary endpoint and demonstrated statistically significant efficacy compared to placebo in treating alopecia areata.

Upadacitinib Superior to Dupilumab in Atopic Dermatitis

The results from the Heads Up study were published in JAMA Dermatology, which demonstrated upadacitinib was superior to dupilumab in treating atopic dermatitis.

FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

FDA Delays Impacting Inflammatory Skin Disease Community

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.